Companies in the pharmaceutical industry continue to add and subtract, and actively embrace new changes in the market

In recent years, under the influence of a series of policies such as medical insurance control fees, the pharmaceutical market is facing a major reshuffle.
In this context, pharmaceutical companies in response to changes are actively doing addition and subtraction
.
"Addition" includes seeking future performance growth points through cooperation and other means; "subtraction" means continuously stripping off non-core businesses and focusing on the main business
.
On the one hand, under the normalization of centralized procurement, the days when pharmaceutical companies "lay down and make money" are gone.
In addition, market competition has become increasingly fierce, and more and more pharmaceutical companies have chosen to cancel their subsidiaries in order to "lighten the burden".
, Spin off non-core pharmaceutical assets, so as to better focus on the main business
.
For example, on November 18, the biotechnology company VTR announced that based on business development and strategic layout considerations, it plans to sell the pharmaceutical business.
The funds obtained from the sale of assets are expected to be used to increase biological enzyme preparations, plant extracts, Investment and industrial upgrading of the three main businesses of animal nutrition and health
.
It is reported that the next step VTR plans to target the industrial enzyme preparations and the "replacement" market, focusing on the development of the three main businesses
.
For another example, on October 25, Puli Pharmaceuticals announced the cancellation of two wholly-owned subsidiaries, one of which is a pharmaceutical company, whose business scope involves the development of pharmaceutical technology and the sale of diagnostic test strips
.
Puli Pharmaceuticals stated that the cancellation decision is based on its development plan and the actual operation of Hainan Zhaoli, in order to further integrate and optimize the existing resource allocation
.
In addition to the two pharmaceutical companies mentioned above, during the year, Xintian Pharmaceutical, TusHoldings, Huitai Medical, Nanjing Hi-Tech, Jinghua Pharmaceutical, Fosun Pharmaceutical and other companies also announced the cancellation of subsidiaries or divestment of part of the pharmaceutical business
.
On the other hand, with the successive introduction of policies to encourage pharmaceutical innovation in recent years, the domestic market for innovative drugs and innovative devices is booming.
In the face of the huge blue ocean of the market, cooperation has become a means for many pharmaceutical companies to promote the development and commercialization of innovative drugs
.
For example, on the evening of November 23, China Heavy Pharmaceutical Holdings announced that its important subsidiary Chongqing Pharmaceuticals and Zhongyuan Huiji have signed the "Strategic Cooperation Framework Agreement".
The two parties will give full play to their respective advantages and carry out in-depth cooperation in the development and maintenance of the IVD market.

.
On the evening of November 21, Hengrui Medicine also issued an announcement stating that it has reached an agreement with CStone Pharmaceuticals (Suzhou) Co.
, Ltd.
to introduce CS1002 anti-CTLA-4 monoclonal antibody from CStone Pharmaceuticals.
Hengrui Pharmaceuticals will obtain CS1002 in Greater China.
The exclusive rights of research and development, registration, production and commercialization
.
The agreement stipulates that Hengrui Pharmaceuticals will pay CStone Pharmaceuticals up to approximately 1.
3 billion yuan in down payment and milestone payments
.
For another example, on the evening of November 18, Kanghua Biological announced that the company reached a strategic cooperation and signed an agreement with Chengdu Xinran Bochuang Biotechnology Co.
, Ltd.
, and the two parties reached a strategy on using the mRNA technology platform to jointly carry out vaccine research against infectious diseases.
Cooperation
.
Xinran Bochuang is mainly responsible for the development and research of vaccines, while Kanghua Biosciences is responsible for providing product R&D funds to Xinran Bochuang and the commercialization of vaccines in addition to part of the research and development and testing work
.
In addition, in the past six months, there has been a surge of cooperation with pharmaceutical companies including Yifan Pharmaceutical and Jichuan Pharmaceutical, and the amount of cooperation involved is huge, which has attracted the attention of the market
.
From the perspective of the industry, in the past, there was more cooperation in R&D and commercialization among multinational pharmaceutical companies.
Domestic cooperation cases, through cooperation, integrating the resources of both parties can better promote the process of R&D and commercialization, and better benefit more patients
.
Regardless of whether it is burden reduction or cooperation, it is the performance of pharmaceutical companies actively embracing and adapting to changes under the new situation, and a new round of reshuffle of the industry has been intensified
.